New chemotherapy drugs for advanced colorectal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests whether a new chemotherapy combination (precemtabart tocentecan, with or without bevacizumab) works better than a standard treatment for colorectal cancer that has spread and stopped responding to previous drugs. The goal is to find treatments that help people live longer with fewer side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Colorectal cancer that has spread to other parts of your body and has progressed despite previous treatments
- You've had no more than 2 previous chemotherapy treatments for your metastatic (spread) cancer
- Good enough general health to handle the study (ECOG score of 0 or 1, meaning you can do most normal activities)
- Ability to swallow pills and follow all study visits and procedures
- Previous chemotherapy side effects have mostly resolved or are mild
- No brain tumors, bowel obstruction, or severe digestive problems that would prevent the medication from working properly
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of chemotherapy (5-FU/LV, irinotecan, and temozolomide) plus bevacizumab in metastatic colon or rectal cancer. It focuses on tumors with an “MGMT silenced” pattern (MGMT gene turned off), which may make some cancers more responsive to these medicines.
This trial tests a combination of two chemotherapy drugs (FTD and tipiracil), a targeted therapy (bevacizumab), and a radiation treatment (radioembolization) for people with colorectal cancer that has spread mainly to the liver and hasn't responded to other treatments. The goal is to see if this combination can shrink tumors and help control the cancer.
This trial tests a new schedule of two drugs—bevacizumab and trifluridine/tipiracil—given every two weeks instead of more often. The goal is to reduce severe low white blood cell counts (neutropenia) while still treating advanced colorectal cancer that has not responded to several previous treatments.
This study tests a new combination of short-course radiation followed by two targeted drugs (fruquintinib and sintilimab) compared to standard therapy (bevacizumab and capecitabine) for people with advanced colorectal cancer who cannot tolerate strong chemotherapy. It aims to see if this gentler approach works as well or better.
This trial tests adding a new immunotherapy drug (QL1706) to standard chemotherapy plus bevacizumab for people with colorectal cancer that has spread and hasn't been treated yet. It aims to see if the combination works better than standard treatment alone.
This trial tests a combination of three drugs (irinotecan, TAS-102, and bevacizumab) for people with metastatic colorectal cancer that has already been treated with oxaliplatin-based chemotherapy. The goal is to see if this three-drug combination works better as a second treatment option.
Hear when a new Metastatic Colorectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.